HER2: an emerging target in colorectal cancer
M Greally, CM Kelly, A Cercek - Current problems in cancer, 2018 - Elsevier
Despite advances in the treatment of metastatic colorectal cancer (CRC) the 5-year survival
of patients with this disease remains low. A small proportion of CRCs overexpress the HER2
oncogene and the effective targeting of this pathway in other malignancies such as breast
and gastric cancer has led to efforts to determine if it can also be exploited as a target in
CRC. Activation of the HER2 pathway as a bypass signalling pathway has been identified as
a mechanism of resistance for antiepidermal growth factor receptor antibody therapy in both …
of patients with this disease remains low. A small proportion of CRCs overexpress the HER2
oncogene and the effective targeting of this pathway in other malignancies such as breast
and gastric cancer has led to efforts to determine if it can also be exploited as a target in
CRC. Activation of the HER2 pathway as a bypass signalling pathway has been identified as
a mechanism of resistance for antiepidermal growth factor receptor antibody therapy in both …